-       Report 
- April 2025
-  185 Pages 
- Global 
   From       €4025EUR$4,500USD£3,541GBP 
            -       Report 
- August 2025
-  184 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
            -       Report 
- August 2025
-  185 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
            -       Report 
- August 2025
-  188 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
            -       Report 
- August 2025
-  188 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
           -       Report 
- October 2025
-  371 Pages 
- Global 
   From       €5233EUR$5,850USD£4,603GBP 
          -       Report 
- October 2025
-  193 Pages 
- Global 
   From       €5233EUR$5,850USD£4,603GBP 
          -       Report 
- October 2025
-  398 Pages 
- Global 
   From       €5233EUR$5,850USD£4,603GBP 
          -       Report 
- September 2025
-  250 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- April 2025
-  200 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- February 2025
-  200 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
            -       Report 
- August 2025
-  197 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
          -       Report 
- April 2023
-  175 Pages 
- Global 
   From       €5276EUR$5,899USD£4,641GBP 
            -       Report 
- May 2024
-  136 Pages 
- Global 
   From       €4941EUR$5,524USD£4,346GBP 
      €5813EUR$6,499USD£5,113GBP 
          -       Report 
- January 2025
-  82 Pages 
- India 
   From       €3131EUR$3,500USD£2,754GBP 
          -       Report 
- October 2024
-  270 Pages 
- China 
   From       €3578EUR$4,000USD£3,147GBP 
          -       Report 
- June 2023
-  83 Pages 
- Global 
   From       €3500EUR$4,192USD£3,186GBP 
          -       Report 
- October 2024
-  135 Pages 
- China 
   From       €1610EUR$1,800USD£1,416GBP 
       
      Cefalexin is an antibiotic used to treat a variety of bacterial infections, including those caused by Streptococcus, Staphylococcus, and E. coli. It is a member of the cephalosporin class of antibiotics, which are used to treat a wide range of infections, including those caused by Gram-positive and Gram-negative bacteria. Cefalexin is commonly used to treat infections of the respiratory tract, urinary tract, skin, and soft tissue. It is also used to treat some sexually transmitted diseases, such as    gonorrhea.
Cefalexin is a widely used antibiotic in the infectious diseases drugs market. It is generally well tolerated and has a low risk of side effects. It is available in both oral and intravenous forms, and is often prescribed as a first-line treatment for bacterial infections.
Some companies in the Cefalexin market include Pfizer, GlaxoSmithKline, Merck, and Sanofi. Show Less   Read more